BVXV: Definitive Collaboration Agreement Signed to Develop Pipeline of NanoAbMay 2nd, 2022
FiledMay 2nd, 2022Based on our probability adjusted DCF model that takes into account potential future revenues from the NanoAb platform, BVXV is valued at $12.00/ADS. This model is highly dependent upon continued clinical success of NanoAb candidates and will be adjusted accordingly based upon future clinical results.